口服芦荟致肝炎
Oral aloe vera-induced hepatitis.
作者信息
Bottenberg Michelle M, Wall Geoffrey C, Harvey Roger L, Habib Shahid
机构信息
Veterans Affairs Medical Center, Des Moines, IA, USA.
出版信息
Ann Pharmacother. 2007 Oct;41(10):1740-3. doi: 10.1345/aph.1K132. Epub 2007 Aug 28.
OBJECTIVE
To report a case of possible oral aloe vera-induced hepatitis.
CASE SUMMARY
A 73-year-old female was admitted to the hospital for acute hepatitis. Extensive laboratory testing did not reveal the cause of the patient's disease. She was asked multiple times whether she was taking any home medications, which she initially denied. It was only after an extensive medication history done by a clinical pharmacist that the patient admitted to using oral aloe vera capsules for constipation. Upon discontinuation of the oral aloe vera, liver markers of hepatotoxicity returned to normal levels.
DISCUSSION
Herbal medications pose an increasing problem in patient safety, as the different types of these products and the number of patients who use them continue to grow. In the US, these products are not subject to the same regulatory scrutiny as prescription medications; thus, safety information can be difficult to obtain. In particular, hepatic toxicity due to herbal agents is poorly described in the medical literature. Aloe vera, often used topically for minor burns, can also be used orally as a laxative or an "anti-aging" agent. According to the Naranjo probability scale, the hepatotoxicity in this case was possibly related to ingestion of oral aloe vera. Additionally, using the Roussel Uclaf Causality Assessment Method for determining drug hepatotoxicity, the patient's symptoms were scored as probably caused by oral aloe vera. The more conservative designation was used in our report.
CONCLUSIONS
With the widespread use of oral aloe vera and other herbal products, clinicians faced with a case of acute hepatitis that is not readily diagnosed should question patients about herbal use.
目的
报告一例可能由口服芦荟引起的肝炎病例。
病例摘要
一名73岁女性因急性肝炎入院。广泛的实验室检查未揭示患者疾病的病因。多次询问她是否正在服用任何家庭用药,她最初予以否认。直到临床药剂师进行了详细的用药史调查后,患者才承认因便秘服用了口服芦荟胶囊。停用口服芦荟后,肝毒性的肝脏指标恢复到正常水平。
讨论
草药制剂对患者安全构成的问题日益严重,因为这些产品的种类以及使用它们的患者数量都在不断增加。在美国,这些产品不像处方药那样受到相同的监管审查;因此,安全信息可能难以获取。特别是,医学文献中对草药制剂引起的肝毒性描述甚少。芦荟通常外用治疗轻度烧伤,也可口服作为泻药或“抗衰老”药物。根据纳伦霍概率量表,该病例中的肝毒性可能与口服芦荟的摄入有关。此外,使用鲁塞尔·优克福因果关系评估法来确定药物性肝毒性,患者的症状被评为可能由口服芦荟引起。我们的报告采用了较为保守的认定。
结论
随着口服芦荟和其他草药产品的广泛使用,面对一例不易诊断的急性肝炎病例时,临床医生应询问患者关于草药使用的情况。